US5003080A
(en)
*
|
1988-02-22 |
1991-03-26 |
Warner-Lambert Company |
Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
|
AU621874B2
(en)
*
|
1988-02-22 |
1992-03-26 |
Warner-Lambert Company |
Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
JP3528186B2
(ja)
*
|
1991-06-24 |
2004-05-17 |
日産化学工業株式会社 |
光学活性キノリンメバロン酸のジアステレオマー塩
|
JP2502605Y2
(ja)
*
|
1992-02-14 |
1996-06-26 |
株式会社大日パレット製作所 |
部品、素材類の取り出し装置
|
CA2150372C
(en)
*
|
1993-01-19 |
2002-08-20 |
Nancy L. Mills |
Stable oral ci-981 formulation and process of preparing same
|
US5298627A
(en)
*
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
US5385929A
(en)
*
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
JP3210552B2
(ja)
*
|
1995-06-07 |
2001-09-17 |
ダイワ精工株式会社 |
魚釣用両軸受型リ−ル
|
RU2158607C2
(ru)
*
|
1995-07-03 |
2000-11-10 |
Санкио Компани Лимитед |
Лечение артериосклероза и ксантомы
|
HRP960312B1
(en)
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
HRP960313B1
(en)
*
|
1995-07-17 |
2002-08-31 |
Warner Lambert Co |
Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
CZ294695B6
(cs)
*
|
1995-07-17 |
2005-02-16 |
Warner-Lambert Company |
Krystalická forma II atorvastatinu nebo jeho hydrátu, farmaceutický přípravek obsahující tuto krystalickou formu II atorvastatinu a její použití v lékařství
|
JPH11515025A
(ja)
*
|
1995-11-02 |
1999-12-21 |
ワーナー−ランバート・コンパニー |
脂質濃度を調節するための方法および医薬組成物
|
US6087511A
(en)
*
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
DE19714343A1
(de)
*
|
1997-04-08 |
1998-10-15 |
Bayer Ag |
Chromatographische Enantiomerentrennung von Lactonen
|
GT199800127A
(es)
*
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
GT199800126A
(es)
*
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US8679534B2
(en)
*
|
1997-12-12 |
2014-03-25 |
Andrx Labs, Llc |
HMG-CoA reductase inhibitor extended release formulation
|
ATE360608T1
(de)
*
|
1997-12-19 |
2007-05-15 |
Pfizer Ireland Pharmaceuticals |
Verfahren zur herstellung von 1,3-diolen
|
US7223428B2
(en)
*
|
1998-01-09 |
2007-05-29 |
Mars Incorporated |
Method of embossing chocolate products
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
WO1999067809A1
(en)
|
1998-06-24 |
1999-12-29 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
CZ20011739A3
(cs)
|
1998-11-20 |
2001-10-17 |
Rtp Pharma Inc. |
Dispergovatelné fosfolipidem stabilizované mikročástice
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
AU3103800A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
|
ATE228012T1
(de)
|
1998-12-23 |
2002-12-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
WO2000038726A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
US6569905B1
(en)
|
1998-12-23 |
2003-05-27 |
G.D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
WO2000038724A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
EA200100707A1
(ru)
|
1998-12-23 |
2001-12-24 |
Джи.Ди.Сирл Ллс |
Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
EP1163203A1
(de)
*
|
1999-03-08 |
2001-12-19 |
Merck & Co., Inc. |
Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure
|
IN191236B
(de)
*
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
HN2000000050A
(es)
|
1999-05-27 |
2001-02-02 |
Pfizer Prod Inc |
Sal mutua de amlodipino y atorvastatina
|
EA200101130A1
(ru)
|
1999-05-27 |
2002-04-25 |
Пфайзер Продактс Инк. |
Общие пролекарства амлодипина и аторвастатина
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
RU2276997C2
(ru)
*
|
1999-08-30 |
2006-05-27 |
Санофи-Авентис Дойчланд Гмбх |
Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
|
US20040063969A1
(en)
*
|
1999-10-18 |
2004-04-01 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
HU226640B1
(en)
*
|
1999-10-18 |
2009-05-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for producing amorphous atorvastatin calcium salt
|
US6646133B1
(en)
|
2000-10-17 |
2003-11-11 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
NZ518822A
(en)
*
|
1999-11-04 |
2004-12-24 |
Andrx Corp |
Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
|
US20020107173A1
(en)
*
|
1999-11-04 |
2002-08-08 |
Lawrence Friedhoff |
Method of treating amyloid beta precursor disorders
|
PT1235799E
(pt)
*
|
1999-11-17 |
2005-05-31 |
Teva Pharma |
Forma polimorfica de atorvastatina-calcio
|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
SI20425A
(sl)
*
|
1999-12-10 |
2001-06-30 |
LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. |
Priprava amorfnega atorvastatina
|
JP2003517038A
(ja)
|
1999-12-17 |
2003-05-20 |
ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド |
結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
|
MXPA02004082A
(es)
*
|
1999-12-17 |
2002-10-11 |
Warner Lambert Res & Dev |
Un proceso para producir calcio de atorvastatin cristalino.
|
JP2003523330A
(ja)
|
2000-02-04 |
2003-08-05 |
チルドレンズ・ホスピタル・リサーチ・ファウンデイション |
アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
|
US20040092574A1
(en)
*
|
2000-02-07 |
2004-05-13 |
Bisgaier Charles Larry |
Statin-Lp(a) inhibitor combinations
|
CA2399396A1
(en)
*
|
2000-02-10 |
2001-08-16 |
Yasuo Sugiyama |
Tnf- .alpha. inhibitors
|
GB0003305D0
(en)
|
2000-02-15 |
2000-04-05 |
Zeneca Ltd |
Pyrimidine derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2001068637A2
(en)
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
EP2382970B1
(de)
|
2000-04-10 |
2013-01-09 |
Teva Pharmaceutical Industries, Ltd. |
Stabile pharmazeutische Zusammensetzungen mit 7-substituierten-3,5-Dihydroxyheptansäuren oder 7-substituierten-3,5-Dihydroxyheptensäuren
|
USRE44578E1
(en)
|
2000-04-10 |
2013-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
ZA200302507B
(en)
*
|
2000-10-12 |
2004-03-31 |
Nisaan Chemical Ind Ltd |
Preventives and remedies for complications of diabetes.
|
PL362472A1
(en)
|
2000-11-03 |
2004-11-02 |
Teva Pharma |
Atorvastatin hemi-calcium form vii
|
GB0027410D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Pfizer Ltd |
Mutual prodrug of amlodipine and atorvastatin
|
US6737430B2
(en)
|
2000-11-09 |
2004-05-18 |
Pfizer, Inc. |
Mutual prodrug of amlodipine and atorvastatin
|
MXPA03004276A
(es)
*
|
2000-11-16 |
2005-04-29 |
Teva Pharma |
Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
|
LT5196B
(lt)
|
2000-11-30 |
2005-02-25 |
Teva Pharmaceutical Industries Ltd. |
Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai
|
IL156055A0
(en)
*
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
US7501450B2
(en)
*
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
ATE420070T1
(de)
*
|
2000-12-27 |
2009-01-15 |
Teva Pharma |
Kristalline formen von atorvastatin
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1724256A3
(de)
*
|
2001-01-09 |
2007-03-21 |
Warner-Lambert Company LLC |
Neues Verfahren zur Synthese von N-Phenyl-5-(4-Fluorphenyl)-1-(2-((2R,4R)-4-Hydroxy-6-Oxotetrahydropyran-2-Yl)Ethyl)-2-Isopropyl-4-Phenyl-1H-Pyrrol-3-Carbonsäureamid
|
WO2002057229A1
(en)
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
*
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
*
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
IN190564B
(de)
*
|
2001-04-11 |
2003-08-09 |
Cadila Heathcare Ltd |
|
US6774112B2
(en)
|
2001-04-11 |
2004-08-10 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
EP1379259A1
(de)
*
|
2001-04-18 |
2004-01-14 |
Genzyme Corporation |
Verfahren zur behandlung von syndrom x mit aliphatischen polyaminen
|
CN1524073A
(zh)
*
|
2001-06-29 |
2004-08-25 |
����-�����ع�˾ |
′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀)
|
US7199261B2
(en)
*
|
2001-07-06 |
2007-04-03 |
Teva Pharmaceutical Industries Ltd |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
US7074818B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Dr. Reddy's Laboratories Limited |
Crystalline forms VI and VII of Atorvastatin calcium
|
US20030114497A1
(en)
*
|
2001-07-31 |
2003-06-19 |
Laman Alani |
Pharmaceutical compositions of amlodipine and atorvastatin
|
KR20040026705A
(ko)
*
|
2001-08-16 |
2004-03-31 |
테바 파마슈티컬 인더스트리즈 리미티드 |
스타틴의 칼슘 염 형태의 제조 방법
|
KR20010099097A
(ko)
*
|
2001-08-29 |
2001-11-09 |
강태구 |
베개와 베개용 높이조절패드의 제조방법.
|
US7563911B2
(en)
*
|
2001-08-31 |
2009-07-21 |
Morepen Laboratories Ltd. |
Process for the preparation of amorphous atorvastin calcium salt (2:1)
|
GB0121436D0
(en)
*
|
2001-09-04 |
2001-10-24 |
Pfizer Ltd |
Biomodulated multiparticulate formulations
|
WO2003027069A1
(en)
*
|
2001-09-24 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
Preparation and use of pyrrole derivatives for treating obesity
|
US6924311B2
(en)
|
2001-10-17 |
2005-08-02 |
X-Ceptor Therapeutics, Inc. |
Methods for affecting various diseases utilizing LXR compounds
|
WO2003033671A2
(en)
*
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
MXPA04003524A
(es)
|
2001-11-02 |
2004-07-23 |
Searle Llc |
Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
WO2003043624A1
(en)
*
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
CA2412012C
(en)
*
|
2001-11-20 |
2011-08-02 |
Ed. Geistlich Soehne Ag Fuer Chemische Industrie |
Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
|
US20060020137A1
(en)
*
|
2001-11-29 |
2006-01-26 |
Limor Tessler |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
AU2002367060A1
(en)
*
|
2001-12-21 |
2003-07-30 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
US7998986B2
(en)
|
2001-12-21 |
2011-08-16 |
Exelixis Patent Company Llc |
Modulators of LXR
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
AU2003207431A1
(en)
|
2002-01-17 |
2003-09-02 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
CZ296967B6
(cs)
*
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
EP1465901A4
(de)
*
|
2002-02-19 |
2006-02-01 |
Teva Pharma |
Verfahren zur desolvatation von atorvastatin hemi-kalzium solvaten und von im wesentlichen lösungsmittelfreiem atorvastatin hemi-kalzium
|
GB0204129D0
(en)
*
|
2002-02-21 |
2002-04-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
KR100828653B1
(ko)
*
|
2002-03-18 |
2008-05-09 |
바이오콘 리미티드 |
목적하는 입자 크기를 갖는 비 결정성 Hmg-CoA리덕타제 억제제
|
DE10212492B4
(de)
*
|
2002-03-21 |
2012-02-02 |
Daimler Ag |
Kolbenpumpe
|
US20050113577A1
(en)
*
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
ITMI20020907A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
HUE027779T2
(en)
|
2002-05-09 |
2016-11-28 |
Brigham & Womens Hospital Inc |
1L1RL-1 is a marker of cardiovascular disease
|
KR101069781B1
(ko)
*
|
2002-05-14 |
2011-10-05 |
프라샌트 인베스트먼츠, 엘엘씨 |
전송 신호를 생성하는 방법
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
ES2315510T3
(es)
*
|
2002-06-13 |
2009-04-01 |
Novartis Ag |
Sales de calcio de estatinas derivadas del indol.
|
US7078430B2
(en)
*
|
2002-07-08 |
2006-07-18 |
Ranbaxy Laboratories Limited |
HMG CoA-reductase inhibitors
|
US20060211761A1
(en)
*
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US20050182106A1
(en)
*
|
2002-07-11 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition for mitigating blood lipid or lowering blood homocysteine
|
US20060062862A1
(en)
*
|
2002-07-23 |
2006-03-23 |
Bernd Haber |
Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances
|
ATE368661T1
(de)
*
|
2002-08-06 |
2007-08-15 |
Warner Lambert Co |
Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US20060122403A1
(en)
*
|
2002-09-03 |
2006-06-08 |
Sanjay Suri |
Atorvastatin calcium form vi or hydrates thereof
|
US20040132728A1
(en)
*
|
2002-09-17 |
2004-07-08 |
Pfizer Inc |
Combinations of atorvastatin and alpha1adrenergic receptor antagonists
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
AU2003282983A1
(en)
*
|
2002-10-23 |
2004-05-13 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
WO2005035001A1
(en)
*
|
2003-09-29 |
2005-04-21 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
AU2003284962B2
(en)
*
|
2002-10-24 |
2009-04-02 |
Palmetto Pharmaceuticals, Llc |
Sustained release L-arginine formulations and methods of manufacture and use
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040102511A1
(en)
*
|
2002-11-21 |
2004-05-27 |
Jitendra Sattigeri |
Substituted pyrrole derivatives
|
EP1424324A1
(de)
*
|
2002-11-28 |
2004-06-02 |
Teva Pharmaceutical Industries Limited |
Kristalline Form F von Atorvastatin
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
JP2006523613A
(ja)
|
2002-12-20 |
2006-10-19 |
エスティ.ジェイムス アソシエイト エルエルシー/フェイバー リサーチ シリーズ |
徐放性医薬投与のための被覆粒子
|
ATE407670T1
(de)
|
2002-12-20 |
2008-09-15 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US20040176425A1
(en)
*
|
2003-01-24 |
2004-09-09 |
Washburn William N. |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
AU2004222436A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
|
SI1603553T1
(sl)
*
|
2003-03-17 |
2012-03-30 |
Japan Tobacco Inc |
Farmacevtski sestavki CETP inhibitorjev
|
WO2004091626A1
(en)
*
|
2003-04-07 |
2004-10-28 |
Osteoscreen, Inc. |
Bone growth stimulation with no/statin and other no modulating combinations
|
CN1774421A
(zh)
*
|
2003-04-14 |
2006-05-17 |
沃尼尔·朗伯有限责任公司 |
制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法
|
AU2003901812A0
(en)
*
|
2003-04-15 |
2003-05-01 |
Vital Health Sciences Pty Ltd |
Phosphates of secondary alcohols
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7772272B2
(en)
*
|
2003-04-28 |
2010-08-10 |
Daiichi Sankyo Company, Limited |
Method for enhancing glucose uptake into warm-blooded animal adipocytes
|
WO2004096278A1
(ja)
*
|
2003-04-28 |
2004-11-11 |
Sankyo Company, Limited |
アディポネクチン産生増強剤
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
EP1636183A1
(de)
*
|
2003-05-16 |
2006-03-22 |
Ambit Biosciences Corporation |
Pyrrolverbindungen und deren verwendung
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
EP2319843B1
(de)
*
|
2003-05-30 |
2013-04-03 |
Ranbaxy Laboratories Limited |
Substituirte Pyrrolderivate und Ihre Verwendung als HMG-CO-Hemmer
|
WO2004105752A1
(en)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives as hmg-coa reductase inhibitors
|
US20040242670A1
(en)
*
|
2003-06-02 |
2004-12-02 |
Sonny Sebastian |
Process for preparation of amorphous atorvastatin calcium
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
EP1643969A2
(de)
*
|
2003-07-11 |
2006-04-12 |
Pro-Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren für die hydrophobe arzneimittelabgabe
|
US7414141B2
(en)
|
2003-07-25 |
2008-08-19 |
Avecia Pharmaceuticals, Ltd. |
Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2005014541A1
(en)
*
|
2003-08-12 |
2005-02-17 |
Biocon Limited |
Novel antihypercholesterolemic compound
|
JP4553899B2
(ja)
|
2003-08-21 |
2010-09-29 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
EP1510208A1
(de)
*
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
CN101318923A
(zh)
*
|
2003-09-17 |
2008-12-10 |
沃尼尔·朗伯有限责任公司 |
[R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸的结晶形式
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
AU2003272082A1
(en)
*
|
2003-10-07 |
2005-04-21 |
Biocon Limited |
Process for the production of atorvastatin calcium
|
WO2005042483A1
(en)
*
|
2003-11-03 |
2005-05-12 |
Biocon Limited |
[r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-((1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- 1h-pyrrole-1-heptanoic acid iron salt
|
JP4839221B2
(ja)
*
|
2003-11-07 |
2011-12-21 |
ジェイ ジェイ ファーマ,インコーポレイテッド |
Hdlを高める併用療法用複合物
|
KR20070054762A
(ko)
*
|
2003-11-12 |
2007-05-29 |
페노믹스 코포레이션 |
헤테로시클릭 보론산 화합물
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AU2004293013B2
(en)
|
2003-11-19 |
2011-04-28 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
MXPA06005915A
(es)
*
|
2003-12-05 |
2006-06-27 |
Warner Lambert Co |
N-alquil pirroles como inhibidores de la hmg-coa reductasa.
|
US20070099891A1
(en)
*
|
2003-12-17 |
2007-05-03 |
Kouichi Kino |
Medicinal compositions and combinations
|
CN100471835C
(zh)
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
WO2005073187A1
(en)
*
|
2004-01-28 |
2005-08-11 |
Apotex Pharmachem Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
EP1563837A1
(de)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolämische Zusammensetzungen enthaltend ein Statin und ein Antiflatulenzmittel
|
EP1718146A2
(de)
*
|
2004-02-13 |
2006-11-08 |
Pro-Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von akne und candida
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
JP4728226B2
(ja)
*
|
2004-02-25 |
2011-07-20 |
興和株式会社 |
Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
|
WO2005079846A1
(ja)
*
|
2004-02-25 |
2005-09-01 |
Kowa Company, Ltd. |
Racタンパク質の核内移行促進剤及びそのスクリーニング方法
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
CA2460935C
(en)
*
|
2004-03-15 |
2010-05-18 |
Brantford Chemicals Inc. |
An improved preparation of atorvastatin
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
SI1727795T1
(sl)
|
2004-03-17 |
2012-05-31 |
Ranbaxy Lab Ltd |
Postopek za pripravo atorvastatin kalcija v amorfni obliki
|
WO2005095374A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Lupin Ltd. |
An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
|
SI21745A
(sl)
*
|
2004-04-09 |
2005-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
|
AP2006003766A0
(en)
*
|
2004-04-16 |
2006-10-31 |
Warner Lambert Co |
Novel imidazoles
|
AU2005232959A1
(en)
*
|
2004-04-16 |
2005-10-27 |
Pfizer Products Inc. |
Process for forming amorphous atorvastatin calcium
|
JP4976281B2
(ja)
*
|
2004-05-03 |
2012-07-18 |
オメガ バイオ‐ファーマ(アイ.ピー.3)リミテッド |
代謝を調節するための材料および方法
|
ES2739493T3
(es)
|
2004-05-05 |
2020-01-31 |
Pfizer Prod Inc |
Formas de sal de de atorvastatina con benetamina
|
US20080262074A1
(en)
*
|
2004-05-24 |
2008-10-23 |
Pfizer, Inc. |
Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
|
EP1748761A4
(de)
*
|
2004-05-27 |
2011-10-12 |
Dexcel Pharma Technologies Ltd |
Lokalisierte kontrollierte absorption von statinen im gastrointestinaltrakt zur erzielung hoher statinspiegel im blut
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
CA2573848A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
MX2007000582A
(es)
*
|
2004-07-16 |
2007-03-30 |
Lek Pharmaceuticals |
Productos de degradacion oxidativa de atorvastatin calcio.
|
CA2672554C
(en)
|
2004-07-20 |
2012-01-03 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
EP1773128A2
(de)
*
|
2004-08-02 |
2007-04-18 |
Pro-Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur verbesserung der chemotherapie mit mikrobiellen zytotoxinen
|
SG155189A1
(en)
*
|
2004-08-06 |
2009-09-30 |
Transform Pharmaceuticals Inc |
Novel fenofibrate formulations and related methods of treatment
|
JP2008509154A
(ja)
*
|
2004-08-06 |
2008-03-27 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なスタチン薬剤組成物および関連治療方法
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
WO2006021968A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Biocon Limited |
PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE
|
US7645888B2
(en)
|
2004-08-27 |
2010-01-12 |
Biocon Limited |
Process for the production of amorphous atorvastatin calcium
|
CA2577848A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Sandoz A/S |
Novel polymorphs of the potassium salt of atorvastatin
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
JP2007512357A
(ja)
*
|
2004-09-28 |
2007-05-17 |
テバ ファーマシューティカル インダストリーズ リミティド |
不純物を実質的に含まないアトルバスタチンカルシウムの形態を調製するための方法
|
AU2005294165B2
(en)
|
2004-10-06 |
2012-02-02 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
ES2272206T1
(es)
*
|
2004-10-18 |
2007-05-01 |
Teva Pharmaceutical Industries Ltd. |
Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
|
NZ555325A
(en)
|
2004-10-27 |
2009-07-31 |
Daiichi Sankyo Co Ltd |
Benzene compound having 2 or more substituents
|
CA2585836A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1817010A4
(de)
*
|
2004-11-22 |
2009-06-17 |
Dexcel Pharma Technologies Ltd |
Kontrollierte resorption von statinen im darm
|
US20090208539A1
(en)
*
|
2004-11-22 |
2009-08-20 |
Adel Penhasi |
Stable atorvastatin formulations
|
AP2007003979A0
(en)
*
|
2004-11-23 |
2007-06-30 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
|
US20090088465A1
(en)
*
|
2004-12-02 |
2009-04-02 |
Stephen Craig Dyar |
Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
|
WO2006062876A2
(en)
|
2004-12-09 |
2006-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20080194548A1
(en)
*
|
2005-01-06 |
2008-08-14 |
Forrest Michael J |
Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
|
WO2006076598A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076568A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Thiazolopyridines as cannabinoid receptor modulators
|
WO2006076597A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006078697A1
(en)
*
|
2005-01-18 |
2006-07-27 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
KR20080016527A
(ko)
*
|
2005-01-31 |
2008-02-21 |
밀란 래보러토리즈, 인크. |
하이드록시화된 네비볼롤을 함유하는 약학적 조성물
|
DE602006004964D1
(de)
*
|
2005-02-10 |
2009-03-12 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
US20080182887A1
(en)
*
|
2005-02-22 |
2008-07-31 |
Sun Pharmaceutical Industries Limited |
Stable Oral Pharmaceutical Composition
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
CA2498978A1
(en)
*
|
2005-02-28 |
2006-08-28 |
Apotex Pharmachem Inc. |
An improved process for the preparation of atorvastatin and intermediates
|
CA2499047A1
(en)
*
|
2005-03-01 |
2006-09-01 |
Apotex Pharmachem Inc. |
Process for producing atorvastatin hemicalcium
|
WO2007046842A2
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
US20080260818A1
(en)
*
|
2005-03-28 |
2008-10-23 |
Dexcel Pharma Technologies Ltd. |
Controlled Absorption of Statins in the Intestine
|
GB2424880A
(en)
*
|
2005-04-06 |
2006-10-11 |
Generics |
Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
|
RO200700700A8
(ro)
*
|
2005-04-08 |
2015-07-30 |
Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag |
Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
|
EP2527337A1
(de)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
|
ES2304911T3
(es)
*
|
2005-05-03 |
2011-05-30 |
Ranbaxy Laboratories Limited |
Sales magnésicas de inhibidores de la reductasa hmg-coa.
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20060275356A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Burgess James W |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AR053495A1
(es)
*
|
2005-05-26 |
2007-05-09 |
Bristol Myers Squibb Co |
Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
|
WO2006130174A2
(en)
|
2005-05-31 |
2006-12-07 |
Mylan Laboratories, Inc. |
Compositions comrising nebivolol
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
KR20080028964A
(ko)
|
2005-06-27 |
2008-04-02 |
엑셀리시스, 인코포레이티드 |
피라졸계 lxr 변조제
|
EP1898922A4
(de)
*
|
2005-07-04 |
2012-03-14 |
Ramu Krishnan |
Verbessertes arzneimittel oder pharmazeutische verbindungen und eine zubereitung davon
|
PL1919466T3
(pl)
|
2005-07-11 |
2012-05-31 |
Cortria Corp |
Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
|
AU2006275694A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
JP2009515816A
(ja)
*
|
2005-08-04 |
2009-04-16 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
|
US20070032665A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Srinivasulu Gudipati |
Preparation of atorvastatin calcium form i
|
CA2619040C
(en)
|
2005-08-15 |
2015-02-10 |
Arrow International Limited |
Crystalline and amorphous sodium atorvastatin
|
BRPI0614279A2
(pt)
|
2005-08-15 |
2012-11-06 |
Arrow Int Ltd |
atorvastatina sódica cristalina e amorfa
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
EP1922301A1
(de)
*
|
2005-09-09 |
2008-05-21 |
Pfizer Science and Technology Ireland Limited |
Herstellung eines atorvastatin-zwischenprodukts
|
EP1922315B1
(de)
*
|
2005-09-09 |
2009-05-27 |
Pfizer Science and Technology Ireland Limited |
Herstellung eines atorvastatin-zwischenprodukts
|
WO2007035395A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
|
US20090216029A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Yatendra Kumar |
Process for the production of atorvastatin calcium in amorphous form
|
CA2547216A1
(en)
*
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US8618115B2
(en)
*
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
SG166829A1
(en)
|
2005-11-08 |
2010-12-29 |
Ranbaxy Lab Ltd |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
DE602006014193D1
(de)
|
2005-11-21 |
2010-06-17 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
|
SI1957452T1
(sl)
|
2005-11-21 |
2010-08-31 |
Warner Lambert Co |
Nove oblike (R-(R*,R*))-2-(4-fluorofenil)-B,B-dihidroksi-5-(1-metiletil)- 3-fenil-4-((fenilamino)karbonil)-1H-prol-1-heptanojske kisline magnezij
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
KR101091376B1
(ko)
*
|
2005-12-01 |
2011-12-07 |
에프. 호프만-라 로슈 아게 |
세로토닌 수송체(sert) 억제제
|
JP2008530146A
(ja)
*
|
2005-12-13 |
2008-08-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
アトルバスタチン・ヘミカルシウムの結晶形及びその調製方法
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20090018118A1
(en)
*
|
2005-12-29 |
2009-01-15 |
Uros Urleb |
Heterocyclic compounds
|
PL1968601T3
(pl)
*
|
2006-01-05 |
2012-03-30 |
Essentialis Inc |
Sole związków otwierających kanały potasowe ATP i ich zastosowanie
|
EP1976873A2
(de)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Modulatoren des humanen glukagon-ähnlichen peptids 1 und ihre anwendung in der behandlung von diabetes und verwandten leiden
|
EP1810667A1
(de)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US7772273B2
(en)
*
|
2006-02-10 |
2010-08-10 |
Lifecycle Pharma A/S |
Stabilized atorvastatin
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2007096751A1
(en)
*
|
2006-02-21 |
2007-08-30 |
Cadila Healthcare Limited |
Process for the preparation of atorvastatin calcium
|
CN101395132A
(zh)
*
|
2006-03-01 |
2009-03-25 |
特瓦制药工业有限公司 |
制备阿托伐他汀半钙的晶形的方法
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
SI22255A
(sl)
*
|
2006-04-14 |
2007-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
|
TW200813039A
(en)
|
2006-04-19 |
2008-03-16 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
US8455640B2
(en)
*
|
2006-05-03 |
2013-06-04 |
Msn Laboratories Limited |
Process for statins and its pharmaceutically acceptable salts thereof
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
US20070265456A1
(en)
*
|
2006-05-09 |
2007-11-15 |
Judith Aronhime |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
JP2009536638A
(ja)
*
|
2006-05-11 |
2009-10-15 |
バイオコン リミテッド |
アトルバスタチンマグネシウムの結晶性形状b4及びその方法
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
EP2021014A1
(de)
*
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Glp-1-rezeptor-modulatoren mit verzögerter freisetzung
|
EP2030025A2
(de)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Mit arteriovaskulären ereignissen assoziierte marker und verfahren zu ihrer verwendung
|
ES2376396T3
(es)
|
2006-06-26 |
2012-03-13 |
Amgen Inc. |
Método para tratar aterosclerosis.
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20090203701A1
(en)
|
2006-06-29 |
2009-08-13 |
Kowa Co., Ltd |
Prophylactic and/or therapeutic agent for rheumatoid arthritis
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
EP2057987B1
(de)
|
2006-08-30 |
2015-03-04 |
Kyushu University, National University Corporation |
Pharmazeutische zusammensetzung mit statin-verkapseltem nanopartikel
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2066788B1
(de)
|
2006-10-02 |
2014-07-23 |
Codexis, Inc. |
Zusammensetzungen und verfahren zur herstellung stereoisomerenreiner statine und synthetische zwischenprodukte dafür
|
HUE028475T2
(en)
*
|
2006-10-09 |
2016-12-28 |
Msn Laboratories Private Ltd |
A novel process for the preparation of statins and their pharmaceutically acceptable salts
|
WO2008044236A2
(en)
*
|
2006-10-10 |
2008-04-17 |
Dexcel Pharma Technologies Ltd. |
Improved release of statins in the intestine
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US20100113802A1
(en)
*
|
2006-11-02 |
2010-05-06 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
|
KR100793321B1
(ko)
*
|
2006-11-29 |
2008-01-11 |
사회복지법인 삼성생명공익재단 |
후각장애 치료 및 예방용 조성물
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
US7834195B2
(en)
*
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
KR100878140B1
(ko)
*
|
2007-01-29 |
2009-01-12 |
한미약품 주식회사 |
아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
KR101012917B1
(ko)
*
|
2007-03-02 |
2011-02-08 |
동아제약주식회사 |
피롤 헵탄산 화합물의 신규한 결정형
|
US20080227846A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
US20080249141A1
(en)
*
|
2007-04-06 |
2008-10-09 |
Palepu Nageswara R |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
KR20090127904A
(ko)
*
|
2007-04-09 |
2009-12-14 |
싸이도우스 엘엘씨. |
스타틴과 항비만제의 복합물
|
EP2474549A1
(de)
|
2007-04-17 |
2012-07-11 |
Bristol-Myers Squibb Company |
Kondensierte heterocyclische als Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-Typ I
|
ES2434215T3
(es)
|
2007-04-18 |
2013-12-16 |
Tethys Bioscience, Inc. |
Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
KR101530393B1
(ko)
|
2007-04-27 |
2015-06-19 |
고쿠리쓰다이가쿠호진 규슈다이가쿠 |
폐질환 치료약
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20080280970A1
(en)
*
|
2007-05-08 |
2008-11-13 |
Czarnik Anthony W |
Deuterium-enriched atorvastatin
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
EP2166843A4
(de)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
Behandlung von virusinfektionen durch modulation von hostzellen-stoffwechselpfaden
|
GB0711250D0
(en)
|
2007-06-12 |
2007-07-18 |
Cbz Chemicals Ltd |
Furanose derivatives
|
AU2008266960A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Diphenyl substituted alkanes
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028407A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028406A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP3103791B1
(de)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
US20110142883A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Actavis Group Ptc Ehf |
Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
|
CA2694590A1
(en)
|
2007-07-26 |
2009-01-29 |
Amgen Inc. |
Modified lecithin-cholesterol acyltransferase enzymes
|
JP2010534644A
(ja)
*
|
2007-07-27 |
2010-11-11 |
シプラ・リミテッド |
医薬組成物およびその製造方法
|
WO2009018065A2
(en)
*
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
RU2569749C2
(ru)
*
|
2007-08-17 |
2015-11-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US20090209608A1
(en)
*
|
2007-08-29 |
2009-08-20 |
Protia, Llc |
Deuterium-enriched asenapine
|
KR100921195B1
(ko)
*
|
2007-10-25 |
2009-10-13 |
주식회사 대웅제약 |
아토르바스타틴의 제조 방법
|
CN101910171A
(zh)
|
2007-11-01 |
2010-12-08 |
百时美施贵宝公司 |
可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
|
WO2009063476A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Biocon Limited |
A crystalline form of atorvastatin hemi magnesium salt and a process thereof
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
CN101945853B
(zh)
|
2007-12-21 |
2014-08-20 |
配体药物公司 |
选择性雄激素受体调节剂(sarm)及其应用
|
CN101205209B
(zh)
*
|
2007-12-25 |
2010-06-02 |
浙江新东港药业股份有限公司 |
一种阿伐他汀中间体的精制方法
|
KR100850558B1
(ko)
*
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
WO2009087938A1
(ja)
*
|
2008-01-10 |
2009-07-16 |
Takeda Pharmaceutical Company Limited |
カプセル製剤
|
CN101965184B
(zh)
|
2008-01-11 |
2015-03-11 |
里亚塔医药公司 |
合成三萜类化合物的制药用途
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
EP2280694A1
(de)
*
|
2008-03-10 |
2011-02-09 |
Dexcel Pharma Technologies Ltd. |
Feuchtigkeitsbeständige wirkstoffformulierungen und verfahren zu ihrer herstellung
|
KR100980379B1
(ko)
|
2008-04-02 |
2010-09-06 |
주식회사 파마코스텍 |
광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
EP2130819A3
(de)
*
|
2008-04-10 |
2009-12-23 |
Ranbaxy Laboratories Limited |
Kristalline Formen von Atorvastatin-Magnesium
|
WO2009148709A1
(en)
*
|
2008-04-16 |
2009-12-10 |
University Of Utah Research Foundation |
Pharmacological targeting of vascular malformations
|
EP2285352A2
(de)
*
|
2008-05-13 |
2011-02-23 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin-zusammensetzungen
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
EP2138178A1
(de)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninone zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) und/oder Asthma
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
WO2010019435A2
(en)
*
|
2008-08-14 |
2010-02-18 |
Teva Pharmaceutical Industries Ltd. |
Solid states of atorvastatin potassium
|
AU2009281122C1
(en)
*
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
EP2161024A1
(de)
|
2008-09-05 |
2010-03-10 |
Universitätsklinikum Hamburg-Eppendorf |
Kombinationspräparat zur Behandlung von Krebs
|
EP2344195A2
(de)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Kombinationstherapie zur behandlung von diabetes und zugehörigen leiden
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
EP2387561A4
(de)
|
2009-01-19 |
2012-07-25 |
Msn Lab Ltd |
Verbessertes verfahren zur herstellung von hochreiner (3r,5s)-7-[2-cyclopropyl-4-(4-fluorphenyl) chinolin-3-yl]-3,5-dihydroxy-6(e)-heptensäure und pharmazeutisch akzeptable salze daraus
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
GB0904104D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Atorvastatin and rosuvastatin derivatives
|
GB0904100D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Use of rosuvastatin lactols as medicaments
|
GB0904102D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Use of atorvastatin lactols as medicaments
|
BRPI1013500A2
(pt)
|
2009-03-27 |
2016-04-05 |
Astrazeneca Uk Ltd |
métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
CN102976996B
(zh)
*
|
2009-05-27 |
2015-08-19 |
峡江和美药业有限公司 |
阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
|
JP5625050B2
(ja)
|
2009-05-28 |
2014-11-12 |
エグゼリクシス パテント カンパニー エルエルシー |
Lxrの調節因子
|
WO2011002422A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility enhancing pharmaceutical formulation
|
WO2011028309A1
(en)
|
2009-09-04 |
2011-03-10 |
University Of Toledo |
PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
MX2012005365A
(es)
|
2009-11-13 |
2012-05-29 |
Bristol Myers Squibb Co |
Formulaciones de tableta de liberacion inmediata.
|
HUE040486T2
(hu)
|
2009-11-13 |
2019-03-28 |
Astrazeneca Ab |
Kétrétegû tabletta készítmények
|
MX2012005425A
(es)
|
2009-11-13 |
2012-06-14 |
Astrazeneca Uk Ltd |
Formulaciones de metformina de masa reducida.
|
KR20210033559A
(ko)
|
2009-11-27 |
2021-03-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
JP2011121949A
(ja)
|
2009-12-14 |
2011-06-23 |
Kyoto Univ |
筋萎縮性側索硬化症の予防および治療用医薬組成物
|
EP2526099B1
(de)
|
2010-01-18 |
2016-03-30 |
MSN Laboratories Limited |
Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
|
CZ201039A3
(cs)
|
2010-01-19 |
2011-07-27 |
Zentiva, K. S |
Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
|
CN103037829A
(zh)
|
2010-02-01 |
2013-04-10 |
儿童医院 |
用于治疗和预防再狭窄的远程缺血调节
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
SG10201502031XA
(en)
|
2010-03-31 |
2015-05-28 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
JP2013523349A
(ja)
|
2010-04-08 |
2013-06-17 |
ザ・ホスピタル・フォー・シック・チルドレン |
外傷性損傷に対する遠隔虚血コンディショニングの使用
|
US8592396B2
(en)
|
2010-04-14 |
2013-11-26 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
US9186392B2
(en)
|
2010-05-05 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
IT1400310B1
(it)
|
2010-05-10 |
2013-05-24 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e statine e loro uso.
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
WO2011152803A1
(en)
|
2010-06-03 |
2011-12-08 |
Mahmut Bilgic |
Water soluble formulation comprising a combination of amlodipine and a statin
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
TR201005326A2
(tr)
|
2010-06-30 |
2012-01-23 |
Bi̇lgi̇ç Mahmut |
Çoklu dozaj formları.
|
RU2016125229A
(ru)
|
2010-07-09 |
2018-12-04 |
БиЭйчВи ФАРМА, ИНК. |
Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
JPWO2012046772A1
(ja)
|
2010-10-06 |
2014-02-24 |
国立大学法人 東京大学 |
リンパ浮腫予防治療剤
|
WO2012056509A1
(ja)
*
|
2010-10-25 |
2012-05-03 |
興和株式会社 |
医薬組成物
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
HU230737B1
(hu)
|
2010-11-16 |
2018-01-29 |
EGIS Gyógyszergyár Nyrt |
Eljárás rosuvastatin só előállítására
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
MX351305B
(es)
|
2011-01-20 |
2017-10-09 |
Merck Sharp & Dohme |
Antagonistas del receptor de mineralocorticoides.
|
MY165159A
(en)
|
2011-01-28 |
2018-02-28 |
Sanofi Biotechnology |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
US10017470B2
(en)
|
2011-01-31 |
2018-07-10 |
Cadila Healthcare Limited |
Treatment for lipodystrophy
|
EP2675440B1
(de)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin-cysteinproteasehemmer
|
JP5705580B2
(ja)
|
2011-02-21 |
2015-04-22 |
公益財団法人微生物化学研究会 |
チオアミド化合物、チオアミド化合物の製造方法、[(4r,6r)−6−アミノエチル−1,3−ジオキサン−4−イル]アセテート誘導体の製造方法、及びアトルバスタチンの製造方法
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
TW201242953A
(en)
|
2011-03-25 |
2012-11-01 |
Bristol Myers Squibb Co |
Imidazole prodrug LXR modulators
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2013004591A1
(en)
|
2011-07-01 |
2013-01-10 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
CA2841552C
(en)
|
2011-07-15 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
ES2953713T3
(es)
|
2011-09-16 |
2023-11-15 |
Regeneron Pharma |
Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
|
WO2013055606A1
(en)
|
2011-10-13 |
2013-04-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
EP2779999A2
(de)
|
2011-11-15 |
2014-09-24 |
Dr. Reddy's Laboratories Ltd. |
Pharmazeutische formulierungen mit atorvastatin und glimepirid
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
CA2858572C
(en)
|
2011-12-08 |
2023-01-17 |
Amgen Inc. |
Human lcat antigen binding proteins and their use in therapy
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013164257A1
(en)
|
2012-04-30 |
2013-11-07 |
F. Hoffmann-La Roche Ag |
New formulation
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
BR112014027952B1
(pt)
|
2012-05-10 |
2022-06-21 |
Bayer Pharma Aktiengesellschaft |
Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
|
TWI601714B
(zh)
|
2012-05-11 |
2017-10-11 |
重植治療公司 |
隱花色素調節劑之含咔唑磺醯胺類
|
EP2849755A1
(de)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
BR112014031310A2
(pt)
|
2012-06-15 |
2017-07-25 |
Genentech Inc |
anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
|
EP2879666B1
(de)
|
2012-08-01 |
2020-04-08 |
Tavakoli, Zahra |
Freifliessende gefrorene zusammensetzungen mit einem therapeutischen mittel
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
EP2925735B1
(de)
|
2012-11-20 |
2019-03-13 |
Lexicon Pharmaceuticals, Inc. |
Inhibitoren der natriumglucose-cotransporter 1
|
KR102161331B1
(ko)
|
2012-11-28 |
2020-09-29 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 조성물 및 방법
|
CN103012240B
(zh)
*
|
2012-12-11 |
2015-05-27 |
保定市龙瑞药物技术有限责任公司 |
一种阿托伐他汀钙的制备方法
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
CN103121964A
(zh)
*
|
2013-01-17 |
2013-05-29 |
复旦大学 |
一种制备阿托伐他汀钙关键中间体的方法
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
CN105209039B
(zh)
|
2013-03-15 |
2018-06-22 |
百时美施贵宝公司 |
Lxr调节剂
|
EP3981388A1
(de)
|
2013-03-21 |
2022-04-13 |
Eupraxia Pharmaceuticals USA LLC |
Injizierbare zusammensetzung mit verzögerter freisetzung und verfahren zur verwendung für die behandlung von entzündungen in gelenken und damit einhergehendem schmerz
|
CN105143203A
(zh)
|
2013-04-17 |
2015-12-09 |
辉瑞大药厂 |
用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
|
MA38385A1
(fr)
|
2013-04-22 |
2017-09-29 |
Cadila Healthcare Ltd |
Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
|
EP3004053B1
(de)
|
2013-05-30 |
2021-03-24 |
Cadila Healthcare Limited |
Verfahren zur herstellung von pyrrolen mit hypolipidämischer hypocholesterämischer aktivität
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
US10494442B2
(en)
|
2013-06-07 |
2019-12-03 |
Sanofi Biotechnology |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
IN2013MU02470A
(de)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
IN2013MU02905A
(de)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
WO2015054089A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CA2929778A1
(en)
|
2013-11-12 |
2015-05-21 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
CN103641764B
(zh)
*
|
2013-11-25 |
2015-12-02 |
北京三泉医药技术有限公司 |
调节血脂的药物组合物
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
WO2015108988A2
(en)
|
2014-01-17 |
2015-07-23 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
JP2017528427A
(ja)
|
2014-07-16 |
2017-09-28 |
サノフィ・バイオテクノロジー |
ヘテロ接合性家族性高コレステロール血症(heFH)を有する患者を処置するための方法
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
EP3194024B1
(de)
|
2014-09-15 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Abzielung auf aneurysma durch modulation von phagozytosesignalwegen
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
ES2838925T3
(es)
|
2015-02-27 |
2021-07-02 |
Univ Leland Stanford Junior |
Terapia de combinación para el tratamiento de la ateroesclerosis
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ap2抗体及び抗原結合剤
|
US10772956B2
(en)
|
2015-08-18 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
|
FR3040303B1
(fr)
*
|
2015-08-27 |
2019-04-05 |
Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger |
Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
PT3206672T
(pt)
|
2015-10-27 |
2018-06-20 |
Eupraxia Pharmaceuticals Inc |
Formulações de libertação prolongada de anestésicos locais
|
CA3022202A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
WO2018104916A1
(en)
|
2016-12-09 |
2018-06-14 |
Cadila Healthcare Limited |
Treatment for primary biliary cholangitis
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
JP7356968B2
(ja)
|
2018-05-08 |
2023-10-05 |
国立大学法人 岡山大学 |
心血管疾患に有用な医薬
|
JP7285015B2
(ja)
|
2018-07-19 |
2023-06-01 |
国立大学法人京都大学 |
多能性幹細胞由来の板状軟骨およびその製造方法
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CA3113037A1
(en)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
|
WO2020130147A1
(ja)
|
2018-12-21 |
2020-06-25 |
国立大学法人京都大学 |
ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
|
JOP20210193A1
(ar)
|
2019-01-18 |
2023-01-30 |
Astrazeneca Ab |
مثبطات pcsk9 وطرق استخدامها
|
CN113316469A
(zh)
|
2019-03-13 |
2021-08-27 |
国立大学法人浜松医科大学 |
主动脉瘤的治疗用医药组合物
|
CR20210669A
(es)
|
2019-05-27 |
2022-05-05 |
Immatics Us Inc |
Vectores víricos y uso de los mismos en terapias celulares adoptivas
|
AU2020408148A1
(en)
|
2019-12-17 |
2022-06-16 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
US20230172996A1
(en)
|
2020-02-21 |
2023-06-08 |
Yoshikazu NAKAOKA |
Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
EP4188338A1
(de)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Zweischichtige tablette mit ezetimib und atorvastatin
|
WO2022040631A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
EP4180036A4
(de)
|
2020-09-29 |
2024-01-31 |
Laboratorios Silanes S A De C V |
Pharmazeutische kombinationen aus statinen und fibraten zur behandlung und prävention von hyperlipidämie und herz-kreislauf-erkrankungen
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|